Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical
role in diverse cellular functions, such as DNA damage detection and repair, transcriptional
regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis
of multiple inflammatory diseases and has become a promising target for the treatment
of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body
of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and
presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric,
pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy
for treating these gastrointestinal disorders. This paper summarises the most significant
current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular
on its role in the development and occurrence of tumours, providing information about
clinical trials and exploring therapeutic possibilities.
Keywords: Biomarker, carcinogenesis, gastrointestinal cancer, PARP inhibitors, poly (ADP-ribose) polymerase-1
(PARP-1), synthetic lethality.
Rights & PermissionsPrintExport